Company* (Symbol)

Product

Description

Indication

Status (Date)

CANCER

Access Pharmaceuticals Inc. (AMEX:AKC)

AP 5280

Polymer platinate; chemotherapeutic agent

Tumors

Company commenced Phase I study to determine dose; study will be conducted at two European sites (9/7)

EntreMed Inc. (ENMD)

Endostatin

Naturally occurring inhibitor of angiogenesis

Cancer

Company initiated its fourth Phase I trial in the Netherlands (9/28)

Ilex Oncology Inc. (ILXO)

NM-3

Orally active small-molecule inhibitor of angiogenesis

Tumors

Company began clinical trials at a research institution in France (9/27)

CARDIOVASCULAR

Medicure Inc. (CDNX:MPH)

Cardoxal

Oral therapeutic

Myocardial infarction and ischemia reperfusion injury

Company filed an IND with Canada's Therapeutic Products Directorate (9/11)

CENTRAL NERVOUS SYSTEM

Biogen Inc. (BGEN)

Avonex

Interferon beta-1a

Primary progressive multiple sclerosis

Company said Avonex has shown potential to affect PPMS in a randomized, controlled trial; data were presented at the 16th annual European Committee for Treatment and Research in Multiple Sclerosis (9/11)

Cephalon Inc. (CEPH)

Provigil (FDA-approved)

Modafinil; oral formulation of synthetic compound that is thought to affect alpha adrenergic receptors in the brain

Narcolepsy

Company launched modafinil in Switzerland (9/20)

INFECTION

Gilead Sciences Inc. (GILD)

AmBisome

amphotericin B liposome for injection

Visceral leishmaniasis

Company announced promising results at ICAAC from a study in India showing 97% of patients were parasite free at 30 days post treatment (9/17)

Maxim Pharmaceuticals Inc. (MAXM)

Maxamine combined with IFN-a

Histamine dihydrochloride; H2 receptor agonist

Hepatitis C

Company announced 48-week results from a Phase II study showing a complete viral response in 61% of all patients (9/14)

Serono SA (NYSE:SRA)

Serostim

Recombinant human growth hormone product

AIDS wasting

The European Commission granted Orphan Medicinal Product designation to Serostim (9/13)

SciClone Pharmaceuticals Inc. (SCLN)

Zadaxin

Thymosin alpha 1; synthetic version of naturally occurring peptide hormone thymosin (immunomodulator)

Hepatitis C

Company received expanded approval in Peru, in addition to hepatitis B (9/28)

The Immune Response Corp. (IMNR)

Remune and HAART

HIV-1 Immunogen and highly active antiretroviral therapy

HIV

Remune is being tested with HAART to suppress the virus after complete treatment cessation; 150 patients are recruited in Australia, Europe and Canada (9/19)

Triangle Pharmaceuticals Inc. (VIRS)

Coviracil, didanosine and efavirenz

Emtricitabine; antiviral nucleoside analogue

HIV

Researchers presented one-year results of a pilot study of a once-a-day HAART regimen combining coviracil with didanosine and efavirenz; data were presented at the 38th Annual Meeting of the Infectious Disease Society of America (9/11)

MISCELLANEOUS

Gliatech Inc. (GLIA)

ADCON-L (FDA- approved)

Anti-adhesion barrier gel (semisynthetic carbohydrate polymer)

Inhibition of post-surgical scarring and adhesions following back surgery

The European Economic Area approved ADCON-L for distribution (9/20)

Oxford Glycosciences plc*

Vevesca (OGT 918)

Oral capsule formulation of a glucosyltransferase inhibitor

Gaucher disease

Researchers presented data on 18 patients who continued an extension protocol at the end of the original study, at the 4th European Working Group on Gaucher Disease (9/8)

Visible Genetics Inc.

Trugene HIV-1 Genotyping Kit

Designed to genetically decode the highly mutagenic HIV-1 from patient serum, identify mutations in the virus and indicate a treatment regimen

HIV

Results from a six-month, randomized study in Europe showed genotypic testing is beneficial; results were presented at ICAAC (9/18)

No Comments